Literature DB >> 10522686

Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis.

F Drago, C Brusati, G Mancardi, A Murialdo, A Rebora.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10522686     DOI： 10.1001/archderm.135.10.1277

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  5 in total

1.  Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis.

Authors:  Antonie Giaever Beiske; Kjell-Morten Myhr
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

2.  Risk-benefit assessment of glatiramer acetate in multiple sclerosis.

Authors:  T Ziemssen; O Neuhaus; R Hohlfeld
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.

Authors:  Dene Simpson; Stuart Noble; Caroline Perry
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 4.  US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles.

Authors:  Steven L Galetta; Clyde Markowitz
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term.

Authors:  Kathleen Costello; Patricia Kennedy; Jo Scanzillo
Journal:  Medscape J Med       Date:  2008-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.